The first half of 2026 has delivered a decisive answer to a question the life sciences industry has been asking for years: is the biotech IPO window finally open again? The drought bottomed out in 2025, when fewer biotechs went public than in any year in at least half a decade. Since then the biotech IPO 2026 class has emerged with record-breaking offerings, strong investor appetite, and a clear shift in market sentiment. From AI-driven drug discovery platforms to obesity therapeutics and novel cancer treatments, the companies that went public in H1 2026 have collectively raised billions, signalling renewed confidence in the sector’s long-term fundamentals.
A Slow Start That Grew Into a Surge
The year did not begin with a bang. According to BioPharma Dive, the first quarter of 2026 saw biotech IPO activity remain at a relatively slow pace in terms of deal count. However, the offerings that did price were significantly larger than those seen in recent years, suggesting that investors were becoming more selective but also more willing to commit substantial capital to the right opportunities.
That cautious optimism gave way to a pronounced acceleration in the second quarter. By the time the BIO International Convention convened in June, the mood among bankers, venture capitalists, and company executives had shifted noticeably. As BioPharma Dive reported from the conference floor, Jim Healy, a managing partner at Sofinnova Investments, summed up simply: “The window’s open.”
Nasdaq itself confirmed the broader trend. The exchange announced that the first half of 2026 was the strongest in US exchange history, with new listings raising $129.3 billion. That headline figure owes most to a single deal, SpaceX, which raised $85.7 billion on its own. Biotech’s share was a small fraction of the total, with venture-backed drug developers raising a little over $4 billion between them by early June, but the sector was well represented among the period’s landmark debuts, and Nasdaq named Parabilis Medicines a marquee listing alongside Cerebras and Quantinuum.
That picture looked different earlier in the year. In April, Morningstar noted that biotech and healthcare were leading the IPO resurgence at a time when technology companies were still holding back ahead of SpaceX’s listing.
The Standout Listings of H1 2026
Several individual offerings defined the biotech IPO 2026 class and set new benchmarks for the industry.
Eikon Therapeutics set the pace in February with a $381 million upsized IPO, at that point the sector’s largest since 2024. The company, led by former Merck Research Chief Roger Perlmutter, is built on Nobel Prize-winning super-resolution microscopy technology applied to oncology drug discovery. The size of the offering, and the calibre of its leadership, set an early tone for the months ahead.
Generate Biomedicines overtook it three weeks later with a $400 million IPO, capping a strong month for biotech listings. Backed by Flagship Pioneering, the same venture creation firm behind Moderna, Generate is developing therapeutics using artificial intelligence and machine learning to design novel protein-based medicines. Much of the proceeds are earmarked for late-stage trials of an anti-TSLP antibody in severe asthma, with further funding for a mid-stage study in chronic obstructive pulmonary disease, giving the platform a clinical test rather than a purely computational one.
The pace intensified in April. Kailera Therapeutics raised $625 million in what was then the largest biotech IPO on record, surpassing Moderna’s $604 million from 2018. The Waltham, Massachusetts-based company is developing a pipeline of obesity treatments licensed from China’s Hengrui Pharmaceuticals, led by ribupatide, an injectable GLP-1 and GIP dual agonist now in global Phase 3 trials. Its shares soared 63 per cent on the first day of trading, reflecting intense investor enthusiasm for the obesity therapeutics space. Chief Executive Ron Renaud told Fierce Biotech that the company “knew we were in a good spot” heading into the offering, citing strong investor interest during the roadshow.
Avalyn Pharma priced a $300 million upsized IPO on 29 April to fund inhaled reformulations of established antifibrotic drugs for pulmonary fibrosis. The stock opened 44 per cent above its $18 offer price on its Nasdaq debut, underscoring appetite for companies addressing areas of significant unmet medical need.
At the end of April, Seaport Therapeutics and Hemab Therapeutics priced their IPOs on the same day, raising a combined $556 million. Seaport, a PureTech Health spinout developing neuropsychiatric medicines for major depressive disorder and generalised anxiety disorder, raised approximately $255 million. Hemab, headquartered in both Cambridge, Massachusetts and Copenhagen, develops therapies for bleeding disorders such as von Willebrand disease and Glanzmann thrombasthenia, and raised $301.5 million. Both offerings were upsized from their initial targets, a recurring theme across the year’s cohort.
Parabilis Sets a New Record
The headline listing of the first half arrived in June when Parabilis Medicines priced an upsized $670 million IPO, the largest venture capital-backed biotech IPO in history. Founded by Harvard University Chemist Gregory Verdine, the company is developing a novel class of therapeutics called helicon peptides, designed to target previously undruggable proteins in cancer and other diseases. Its lead programme targets the Wnt/beta-catenin pathway in desmoid tumours.
Parabilis filed for its IPO just one day after announcing a strategic collaboration with Regeneron Pharmaceuticals worth up to $2.3 billion to develop antibody-helicon conjugates. That agreement included a $50 million upfront payment and a commitment from Regeneron to invest $75 million in the company’s next equity round, which the IPO duly became. Regeneron took 4.17 million shares at $18 each in a concurrent private placement, bringing total capital raised around the listing to approximately $745 million. On its first day of Nasdaq trading, shares surged 58 per cent.
Parabilis still held the record a week later when Kardigan, a cardiovascular biotech developing therapies for genetic cardiomyopathy, aortic valve stenosis and severe hypertension, priced its own upsized IPO at $400 million on 17 June. Priced at $16 per share, the high end of its range, it was the fourth biotech offering of the year to reach at least $400 million, a level rarely seen since 2021.
What Is Driving the Rebound?
Several converging factors explain the revival. The most significant is the broader recovery in biopharma dealmaking. Biotech mergers and acquisitions had reached $106 billion across 201 deals by early June, putting the industry on track for its best year of dealmaking since before the pandemic, according to CNBC. That M&A activity has created a virtuous cycle: as large pharmaceutical companies acquire clinical-stage biotechs at premium valuations, it validates the sector’s pipeline assets and gives venture capital firms a clear path to returns, which in turn encourages more IPO activity.
Market conditions have helped too, though not through cheaper money. Equity markets reached record highs during the spring, and improving risk appetite reopened the listing calendar across sectors, biotech included.
Perhaps most importantly, the quality of the companies coming to market has improved. As BioSpace noted, the strongest first-day performances have been concentrated among derisked biotechs, those with clinical data, validated platforms, or strategic partnerships with established pharmaceutical companies. Pre-clinical companies raising at that scale on concept alone have become far less common, at least for now. Investors are demanding substance, and the companies that have delivered it have been rewarded with strong pricing and first-day performance.
Therapeutic Areas in Focus
The biotech IPO 2026 class reflects the therapeutic priorities that are commanding the most investor attention. Oncology remains dominant, with Parabilis, Eikon, and several smaller listings all focused on cancer drug development. The obesity and metabolic disease space, driven by the commercial success of GLP-1 receptor agonists from Novo Nordisk and Eli Lilly, has drawn significant interest, as Kailera’s debut demonstrated.
AI-enabled drug discovery has also emerged as a distinct category. Generate Biomedicines’ successful listing suggests that investors are willing to back platform companies in this space, provided they can demonstrate tangible clinical progress rather than theoretical computational advantages alone.
Rare disease and neuropsychiatric conditions have likewise attracted significant capital. Seaport was the first biotech focused on neurological disorders to price an offering in 2026, and alongside Hemab it shows that specialist therapeutic areas remain attractive to public market investors when the clinical rationale is compelling.
Performance has not tracked the headline raises. The year’s best-performing listing across all US sectors has been Veradermics, a dermatology company developing a treatment for pattern hair loss, whose shares have risen more than fivefold since February on a raise of $256 million, well below the largest offerings of the half.
Risks and Cautions
Not every aspect of the biotech IPO 2026 landscape is uniformly positive. Most of the 2026 class has traded at or above its offer price, but not all, and at least one of the year’s larger early listings was down more than 20 per cent within a month of debuting. Scale at pricing does not guarantee aftermarket performance.
There are also concerns about crowding, though not from biotech itself. The American Action Forum, a US public policy institute, has argued that the sector’s recovery could be swamped by listings from an entirely different part of the market. With several of the largest technology and AI companies weighing offerings of their own, it questioned how much investor attention the IPO calendar can absorb at once, and how much capital would still be available later in the year.
The relationship between IPO exits and M&A exits is another dynamic to watch. The two have largely reinforced each other this year, but not always. Fierce Biotech reported that an unusually aggressive burst of dealmaking, including seven transactions worth over $1 billion each in the final twelve days of March, coincided with a near-total pause in new listings that month, prompting suggestions that a hot acquisition market can pull companies away from the public route.
Macroeconomic uncertainty, including ongoing trade policy developments and their potential effects on pharmaceutical supply chains and pricing, remains a background risk that could temper enthusiasm in the second half of the year.
What It Signals for H2 and Beyond
The strength of the first half suggests that the biotech IPO market has moved past the crisis of confidence that bottomed out last year, a shift already visible by mid-June. The pipeline of companies preparing S-1 filings continues to grow, and bankers at the BIO conference indicated that several additional large offerings are expected before the end of 2026.
However, the market’s message is clear: quality matters. The companies that have thrived are those with differentiated science, experienced management teams, clinical data to support their valuations, and in many cases strategic partnerships that de-risk their programmes. For the broader biotech ecosystem, that selectivity is arguably a healthy development, one that rewards companies with clinical evidence behind their valuations.
For investors, clinicians, and industry observers, the biotech IPO class of 2026 represents more than a collection of individual stock market listings. Read alongside the year’s record run of billion-dollar biotech acquisitions, it is a barometer of where capital sees the most promising opportunities, from undruggable oncology targets to AI-designed medicines and next-generation metabolic therapies. The first half of the year has delivered a compelling opening chapter; the second half will reveal whether this renewed confidence can be sustained.
